A5063293794- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Cancer Immunotherapy and Biomarkers
- Cell Adhesion Molecules Research
- Autoimmune and Inflammatory Disorders
- Immune cells in cancer
- Cancer, Hypoxia, and Metabolism
- Lipid metabolism and disorders
- Abdominal Surgery and Complications
- Immune Cell Function and Interaction
Ghent University
2021-2024
VIB-UGent Center for Inflammation Research
2021-2024
Ghent University Hospital
2021-2022
Background: Data on ustekinumab and vedolizumab in the elderly inflammatory bowel disease (IBD) population are limited. The aim of current study was to assess safety effectiveness both an real-life population. Methods: A multicentric retrospective performed IBD patients who started or between 2010 2020. Clinical endoscopic remission rates (serious) adverse events (AE) were assessed. Results: total 911 included, with 171 (19%) aged above 60 (111 VDZ, UST). Elderly treated had increased risk...
Extra-intestinal manifestations are frequently reported in inflammatory bowel diseases. However, data comparing the effect of vedolizumab and ustekinumab on articular extra-intestinal limited. The aim here was to evaluate differences new-onset evolution pre-existing joint during both treatments.An international multicentre retrospective study performed disease patients who started or between May 2010 December 2020. were assessed at baseline evaluated throughout 2-year follow-up. Arthropathy...
Environmental hypoxia and hypoxia-induced signalling in the gut influence inflammatory bowel disease pathogenesis, however data is limited to colitis. Hence, we investigated effect of environmental immune cell-specific deletion oxygen sensor prolyl hydroxylase (PHD) 1 a Crohn’s like ileitis mouse model. Therefore, 5-week-old C57/BL6 TNF∆ARE/+ mice wildtype (WT) littermates were housed normoxia (21% O2) or (8% for 10 weeks. Systemic inflammation was assessed by haematology. Distal ileal...
Abstract Background Extra-intestinal manifestations (EIM) are frequently reported in inflammatory bowel diseases (IBD). Although the efficacy of TNF inhibitors is well documented, data regarding effect vedolizumab (VDZ) and ustekinumab (UST) limited. Theoretically, advantage VDZ, i.e. gut-selectivity, may reduce on EIM while systemic UST be benefit. Therefore, we evaluated differences new onset evolution during both treatments. Methods An international multicentric retrospective study was...